Catalyst Calendar • Endpoint Arena

Catalyst Calendar

Thu, Jul 2, 2026

1 updates

8:00 AM

Kyowa Kirin Highlights Publication in the New England Journal of Medicine of BridgeBio’s Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

kyowakirin.com

Wed, Jun 24, 2026

1 updates

8:00 AM

Kyowa Kirin Highlights Upcoming Presentation of Phase 3 PROPEL 3 Results for Oral Infigratinib in Achondroplasia at ICCBH 2026

Presentation / Abstract • Phase 3ICCBH 2026 presentation Wed, Jun 24, 2026kyowakirin.com

Fri, Jun 12, 2026

1 updates

8:00 AM

Kura Oncology and Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination in Newly Diagnosed AML

Trial Resultskyowakirin.com

Tue, Jun 9, 2026

1 updates

8:00 AM

Kyowa Kirin Publishes “Integrated Report 2025”

kyowakirin.com

Wed, Jun 3, 2026

1 updates

8:00 AM

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1 -m AML

kyowakirin.com

Wed, May 13, 2026

1 updates

8:00 AM

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Presentation / Abstractkyowakirin.com

Thu, May 7, 2026

2 updates

8:00 AM

Kyowa Kirin Plans the Creation of State-of-the-Art Research Hub to Further Strengthen Drug Discovery Capabilities

kyowakirin.com

8:00 AM

Announcement of Consolidated Financial Results Fiscal 2026 First Quarter

kyowakirin.com

Fri, Apr 24, 2026

1 updates

8:00 AM

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

kyowakirin.com